English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Plasmepsin V (Plm V) is an essential aspartic protease required for survival of the malaria parasite,  Plasmodium falciparum (Pf) . Plm V is required for cleaving the PEXEL motifs of many  Pf  proteins and its inhibition leads to a knockout effect, indicating its suitability as potential drug target. To decipher new inhibitors of  Pf Plm V, molecular docking of four HIV-1 protease inhibitors active against  Pf PlmV was performed on Glide module of Schrödinger suite that supported saquinavir as a lead drug, and therefore, selected as a control. Saquinavir contains an important hydroxyethylamine (HEA) pharmacophore, which was utilized as backbone coupled with piperazine scaffold to build new library of compounds. Newly designed HEA compounds were screened virtually against Plm V. Molecular docking led to a few hits ( 1  and  3 ) with higher docking score over the control drug. Notably, compound  1  showed the highest docking score (–11.90 kcal/mol) and XP Gscore (–11.948 kcal/mol). The Prime MMGBSA binding free energy for compound  1  (–60.88 kcal/mol) and  3  (–50.96 kcal/mol) was higher than saquinavir (–37.51 kcal/mol). The binding free energy for the last frame of molecular dynamic simulation supported compound  1  (–92.88 kcal/mol) as potent inhibitor of  Pf Plm V over saquinavir (–72.77 kcal/mol), and thus, deserves experimental validations in culture and subsequently in animal models. Communicated by Ramaswamy H. Sarma

In silico validation of novel inhibitors of malarial aspartyl protease, plasmepsin V and antimalarial efficacy prediction